{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:27:39Z","timestamp":1786580859637,"version":"build-2736575974"},"reference-count":107,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sylvester Comprehensive Cancer Center and National Cancer Institute of the National Institutes of Health","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poly ADP-ribose polymerase (PARP) inhibitors (PARPi) have revolutionized cancer care across multiple solid tumor types for patients with BRCA mutations and homologous recombination deficient malignancies. Sentinel trials for PARPi, however, have had limited participation from non-European populations, limiting interpretation of results, dosing strategies, and quality-of-life implications in these patients. Our objective was to review participation by race and ethnicity in sentinel PARPi trials across disease sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed\/MEDLINE. Core search terms included \u201cPARP inhibitor\u201d and the disease sites of interest (breast, ovary, prostate, and pancreas). A review of each sentinel trial was conducted utilizing data from ClinicalTrials.gov to obtain and\/or confirm demographic information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sentinel PARPi trials across all disease sites included populations that were predominantly White. TRITON2 (prostate) had the highest proportion of Black participants (5.8%), while Black participation in breast and ovarian cancer trials was almost always &amp;lt;3%. Missing data on race and ethnicity was common, and highest in TRITON2 and TRITON3 (\u223c20%, prostate) and ARIEL3 (13.3%, ovary). Aggregation into an \u201cother\u201d category was highest in EMBRACA (17.2%). Hispanic ethnicity was reported in only 5 of the 14 trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is overwhelming underrepresentation of racial and ethnic minorities in sentinel PARPi trials. Systemic issues in accepted clinical trial infrastructure, including reporting practices, site selection, protocol biases, and access challenges are all likely etiologies. Addressing the complexity of inclusion in global oncology research is still a crucial need to ensure cancer care equity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag291","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:44:27Z","timestamp":1784893467000},"source":"Crossref","is-referenced-by-count":0,"title":["Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review"],"prefix":"10.1093","volume":"31","author":[{"given":"Ashleigh","family":"Swearingen","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center , Miami, FL 33136,","place":["United States"]},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Miami Miller School of Medicine , Miami, FL 33136,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala","family":"Audu","sequence":"additional","affiliation":[{"name":"Federal University of Health Sciences Azare (FUHSA) , Azare,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamidu","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH) , Zaria,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Mustapha","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH) , Zaria,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekunle","family":"Oguntayo","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH) , Zaria,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisah","family":"Yahya","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH) , Zaria,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar","family":"Bello","sequence":"additional","affiliation":[{"name":"Federal University of Health Sciences Azare (FUHSA) , Azare,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raleigh","family":"Butler","sequence":"additional","affiliation":[{"name":"University of the West Indies-Nassau , Nassau, Bahamas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darron","family":"Halliday","sequence":"additional","affiliation":[{"name":"University of the West Indies-Nassau , Nassau, Bahamas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saida","family":"Bowe","sequence":"additional","affiliation":[{"name":"University of the West Indies-Nassau , Nassau, Bahamas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Jordan","sequence":"additional","affiliation":[{"name":"Broward Health , Fort Lauderdale, FL 33316,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Hew","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Florida-Jacksonville , Jacksonville, FL 32209,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Miami Miller School of Medicine , Miami, FL 33136,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Patricia","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Miami Miller School of Medicine , Miami, FL 33136,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isildinha M","family":"Reis","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Department of Public Health Sciences, University of Miami Miller School of Medicine , Miami, FL 33136,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"George","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center , Miami, FL 33136,","place":["United States"]},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Miami Miller School of Medicine , Miami, FL 33136,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-7327","authenticated-orcid":false,"given":"Matthew","family":"Schlumbrecht","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center , Miami, FL 33136,","place":["United States"]},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Miami Miller School of Medicine , Miami, FL 33136,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"2026081219362938700_oyag291-B1","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1017\/pcm.2022.4","article-title":"Impact of structural racism on inclusion and diversity in precision oncology: a scoping and critical review of the literature","volume":"1","author":"Genevi\u00e8ve","year":"2022","journal-title":"Camb Prisms Precis Med"},{"key":"2026081219362938700_oyag291-B2","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026081219362938700_oyag291-B3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","article-title":"Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"},{"key":"2026081219362938700_oyag291-B4","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026081219362938700_oyag291-B5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ygyno.2025.11.020","article-title":"Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in ovarian cancer: a society of gynecologic oncology clinical practice review","volume":"204","author":"Washington","year":"2026","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B6","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B8","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026081219362938700_oyag291-B9","doi-asserted-by":"publisher","first-page":"e2400015","DOI":"10.1200\/GO.24.00015","article-title":"Global equity in clinical trials: an ASCO policy statement","volume":"10","author":"Al Sukhun","year":"2024","journal-title":"JCO Glob Oncol."},{"key":"2026081219362938700_oyag291-B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ygyno.2023.07.008","article-title":"Intra-racial disaggregation reveals associations between nativity and overall survival in women with endometrial cancer","volume":"176","author":"Mercadel","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2022.01.032","article-title":"Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers","volume":"165","author":"Wagar","year":"2022","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B12","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaoncol.2016.1854","article-title":"Racial\/ethnic disparities in genomic sequencing","volume":"2","author":"Spratt","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026081219362938700_oyag291-B13","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41467-025-57216-8","article-title":"Equitable machine learning counteracts ancestral bias in precision medicine","volume":"16","author":"Smith","year":"2025","journal-title":"Nat Commun"},{"key":"2026081219362938700_oyag291-B14","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1038\/d41586-021-03715-9","article-title":"Why Black women with ovarian cancer require greater focus","volume":"600","author":"George","year":"2021","journal-title":"Nature"},{"key":"2026081219362938700_oyag291-B15","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/ijerph22081220","article-title":"Precision medicine for cancer and health equity in Latin America: generating understanding for policy and health system shaping","volume":"22","author":"Gonz\u00e1lez","year":"2025","journal-title":"Int J Environ Res Public Health"},{"key":"2026081219362938700_oyag291-B16","doi-asserted-by":"publisher","first-page":"e1400","DOI":"10.1002\/cnr2.1400","article-title":"Recommendations for streamlining precision medicine in breast cancer care in Latin America","volume":"4","author":"Alvarado-Cabrero","year":"2021","journal-title":"Cancer Rep"},{"key":"2026081219362938700_oyag291-B17","doi-asserted-by":"publisher","first-page":"101680","DOI":"10.1016\/j.gore.2025.101680","article-title":"Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer","volume":"57","author":"Abdul-Aziz","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"2026081219362938700_oyag291-B18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ygyno.2020.12.015","article-title":"Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients","volume":"160","author":"Liang","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B19","doi-asserted-by":"publisher","first-page":"891149","DOI":"10.3389\/fphar.2022.891149","article-title":"Cost-effectiveness of poly ADP-ribose polymerase inhibitors in cancer treatment: a systematic review","volume":"13","author":"Chan","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026081219362938700_oyag291-B20","doi-asserted-by":"publisher","first-page":"e2346494","DOI":"10.1001\/jamanetworkopen.2023.46494","article-title":"Racial and ethnic disparities in clinical trial enrollment among women with gynecologic cancer","volume":"6","author":"Khadraoui","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026081219362938700_oyag291-B21","doi-asserted-by":"publisher","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026081219362938700_oyag291-B22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ygyno.2020.01.040","article-title":"Are ethnic and racial minority women less likely to participate in clinical trials?","volume":"157","author":"Patel","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cct.2014.08.004","article-title":"Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review","volume":"39","author":"Heller","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"2026081219362938700_oyag291-B24","author":"BRCA1 and BRCA2 (PDQ\u00ae)"},{"key":"2026081219362938700_oyag291-B25","doi-asserted-by":"publisher","first-page":"560857","DOI":"10.1155\/2013\/560857","article-title":"Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent","volume":"2013","author":"Rebbeck","year":"2013","journal-title":"Prostate Cancer"},{"key":"2026081219362938700_oyag291-B26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11606-020-06064-x","article-title":"Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center","volume":"36","author":"Chapman-Davis","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2026081219362938700_oyag291-B27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10549-010-1156-9","article-title":"A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas","volume":"125","author":"Donenberg","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2026081219362938700_oyag291-B28","doi-asserted-by":"publisher","first-page":"e210307","DOI":"10.1001\/jamanetworkopen.2021.0307","article-title":"Gene sequencing for pathogenic variants among adults with breast and ovarian cancer in the Caribbean","volume":"4","author":"George","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026081219362938700_oyag291-B29","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1634\/theoncologist.2015-0416","article-title":"Founder and recurrent mutations in BRCA1 and BRCA2 genes in Latin American countries: state of the art and literature review","volume":"21","author":"Ossa","year":"2016","journal-title":"Oncologist"},{"key":"2026081219362938700_oyag291-B30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026081219362938700_oyag291-B31","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026081219362938700_oyag291-B32","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"2026081219362938700_oyag291-B33","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B34","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B35","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"\u201cTalazoparib for advanced germline BRCA-mutated breast cancer.\u201d","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B36","author":"Pfizer","year":"2021"},{"key":"2026081219362938700_oyag291-B37","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B38","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026081219362938700_oyag291-B39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B40","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-Mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081219362938700_oyag291-B41","author":"AstraZeneca","year":"2025"},{"key":"2026081219362938700_oyag291-B42","author":"AstraZeneca","year":"2025"},{"key":"2026081219362938700_oyag291-B43","author":"Pharmaand","year":"2023"},{"key":"2026081219362938700_oyag291-B44","author":"Tesaro, Inc","year":"2026"},{"key":"2026081219362938700_oyag291-B45","author":"Tesaro, Inc","year":"2023"},{"key":"2026081219362938700_oyag291-B46","author":"AstraZeneca","year":"2026"},{"key":"2026081219362938700_oyag291-B47","author":"AstraZeneca","year":"2026"},{"key":"2026081219362938700_oyag291-B48","author":"AstraZeneca","year":"2023"},{"key":"2026081219362938700_oyag291-B49","author":"Pharmaand","year":"2023"},{"key":"2026081219362938700_oyag291-B50","author":"Pharmaand","year":"2025"},{"key":"2026081219362938700_oyag291-B51","author":"AstraZeneca","year":"2023"},{"key":"2026081219362938700_oyag291-B52","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1007\/s12672-025-03487-y","article-title":"Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Discov Oncol"},{"key":"2026081219362938700_oyag291-B53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ygyno.2017.09.002","article-title":"Variation in type II endometrial cancer risk by Hispanic subpopulation: an exploratory analysis","volume":"147","author":"Schlumbrecht","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B54","doi-asserted-by":"publisher","first-page":"e241388","DOI":"10.1001\/jamahealthforum.2024.1388","article-title":"Race and ethnicity representation in phase 2\/3 oncology clinical trial publications","volume":"5","author":"Taparra","year":"2024","journal-title":"JAMA Health Forum"},{"key":"2026081219362938700_oyag291-B55","doi-asserted-by":"publisher","first-page":"e2400636","DOI":"10.1200\/GO-24-00636","article-title":"Impact of global enrollment on race, ethnicity, and age representation in pivotal gynecologic cancer trials leading to US Food and Drug Administration drug approvals","volume":"11","author":"Khan","year":"2025","journal-title":"JCO Glob Oncol."},{"key":"2026081219362938700_oyag291-B56","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamaoncol.2020.7478","article-title":"An analysis of contemporary oncology randomized clinical trials from low\/middle-income vs high-income countries","volume":"7","author":"Wells","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026081219362938700_oyag291-B57","author":"World Bank Country and Lending Groups \u2013 World Bank Data Help Desk","year":"2026"},{"key":"2026081219362938700_oyag291-B58","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(23)00182-1","article-title":"Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments","volume":"24","author":"McIntosh","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026081219362938700_oyag291-B59","author":"Population, Total for Low and Middle Income Countries"},{"key":"2026081219362938700_oyag291-B60","author":"University of Miami","year":"2025"},{"key":"2026081219362938700_oyag291-B61","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ygyno.2023.05.006","article-title":"Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: a joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)","volume":"174","author":"Pothuri","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B62","author":"World Bank Open Data","year":"2026"},{"key":"2026081219362938700_oyag291-B63","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1186\/s12889-024-20983-y","article-title":"Current status and trends in thalassemia burden across South, East and Southeast Asia, 1990-2021 a systematic analysis for the global burden of disease study 2021","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Public Health"},{"key":"2026081219362938700_oyag291-B64","doi-asserted-by":"publisher","first-page":"e2432475","DOI":"10.1001\/jamanetworkopen.2024.32475","article-title":"Cancer trial eligibility and therapy modifications for individuals with Duffy null\u2013associated neutrophil count","volume":"7","author":"Hibbs","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026081219362938700_oyag291-B65","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1001\/jama.2023.7467","article-title":"Development of Duffy null-specific absolute neutrophil count reference ranges","volume":"329","author":"Merz","year":"2023","journal-title":"JAMA"},{"key":"2026081219362938700_oyag291-B66","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/bloodadvances.2022007680","article-title":"White blood cell ranges and frequency of neutropenia by Duffy genotype status","volume":"7","author":"Bagheri","year":"2023","journal-title":"Blood Adv"},{"key":"2026081219362938700_oyag291-B67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv"},{"key":"2026081219362938700_oyag291-B68","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.5010","article-title":"Expansion of recommendations for hereditary cancers","volume":"23","author":"Maxwell","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"2026081219362938700_oyag291-B69","year":"2026"},{"key":"2026081219362938700_oyag291-B70","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10689-026-00530-x","article-title":"Hereditary ovarian cancer in women with African ancestry: a scoping review","volume":"25","author":"Rossouw","year":"2026","journal-title":"Fam Cancer"},{"key":"2026081219362938700_oyag291-B71","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026081219362938700_oyag291-B72","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s13063-017-2099-9","article-title":"Barriers to the conduct of randomised clinical trials within all disease areas","volume":"18","author":"Djurisic","year":"2017","journal-title":"Trials"},{"key":"2026081219362938700_oyag291-B73","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","article-title":"Priorities for cancer research in low- and middle-income countries: a global perspective","volume":"28","author":"Pramesh","year":"2022","journal-title":"Nat Med"},{"key":"2026081219362938700_oyag291-B74","doi-asserted-by":"publisher","first-page":"e0000583","DOI":"10.1371\/journal.pgph.0000583","article-title":"Funders: the missing link in equitable global health research?","volume":"2","author":"Charani","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2026081219362938700_oyag291-B75","doi-asserted-by":"publisher","first-page":"e002287","DOI":"10.1136\/bmjgh-2020-002287","article-title":"Regulating international clinical research: an ethical framework for policy-makers","volume":"5","author":"Aguilera","year":"2020","journal-title":"BMJ Glob Health"},{"key":"2026081219362938700_oyag291-B76","doi-asserted-by":"publisher","first-page":"764239","DOI":"10.3389\/fped.2021.764239","article-title":"Generating evidence from contextual clinical research in low- to middle income countries: a roadmap based on theory of change","volume":"9","author":"Hasan","year":"2021","journal-title":"Front Pediatr"},{"key":"2026081219362938700_oyag291-B77","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026081219362938700_oyag291-B78","doi-asserted-by":"publisher","first-page":"104086","DOI":"10.1016\/j.esmoop.2024.104086","article-title":"Globalization of clinical trials in oncology: a worldwide quantitative analysis","volume":"10","author":"Izarn","year":"2025","journal-title":"ESMO Open"},{"key":"2026081219362938700_oyag291-B79","doi-asserted-by":"publisher","first-page":"e217075","DOI":"10.1001\/jamanetworkopen.2021.7075","article-title":"Evaluation of drug trials in high-, middle-, and low-income countries and local commercial availability of newly approved drugs","volume":"4","author":"Miller","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026081219362938700_oyag291-B80","doi-asserted-by":"publisher","first-page":"68.e1","DOI":"10.1016\/j.ajog.2021.01.029","article-title":"Patient cost-sharing during poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer","volume":"225","author":"Harrison","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2026081219362938700_oyag291-B81","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40258-021-00670-4","article-title":"Comparison of prices and affordability of cancer medicines in 16 countries in Europe and Latin America","volume":"20","author":"Moye-Holz","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"2026081219362938700_oyag291-B82","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/cancers12071929","article-title":"Economic evaluation of population-based BRCA1\/BRCA2 mutation testing across multiple countries and health systems","volume":"12","author":"Manchanda","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026081219362938700_oyag291-B83","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3332\/ecancer.2024.1653","article-title":"Implementing precision oncology in Latin America to improve patient outcomes: the status quo and a call to action for key stakeholders and decision-makers","volume":"18","author":"de Castilla","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"2026081219362938700_oyag291-B84","author":"Average Income around the World"},{"key":"2026081219362938700_oyag291-B85","author":"Breast Cancer Genetic Testing Cost: Is It Worth It?"},{"key":"2026081219362938700_oyag291-B86","author":"Krogh-Jespersen"},{"key":"2026081219362938700_oyag291-B87","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ygyno.2020.12.039","article-title":"The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: who bears the cost?","volume":"160","author":"Goldsberry","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026081219362938700_oyag291-B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071929","article-title":"Economic evaluation of population-based BRCA1\/BRCA2 mutation testing across multiple countries and health systems","volume":"12","author":"Manchanda","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026081219362938700_oyag291-B89","author":"Information about olaparib | olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | Guidance | NICE"},{"key":"2026081219362938700_oyag291-B90","article-title":"Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644] | consultations | NICE","author":"Information about niraparib"},{"key":"2026081219362938700_oyag291-B91"},{"key":"2026081219362938700_oyag291-B92","author":"Lynparza"},{"key":"2026081219362938700_oyag291-B93","author":"Hereditary Breast and Ovarian Cancer Test"},{"key":"2026081219362938700_oyag291-B94","author":"Breast Cancer Focused Gene Panel | Sonic Genetics","year":"2026"},{"key":"2026081219362938700_oyag291-B95","author":"How to Get Olaparib (Lynparza\u00ae) for Cancer Treatment - A Detailed Guid"},{"key":"2026081219362938700_oyag291-B96","author":"Lab Test Prices In Kenya 2026 | 450+ Tests From KES 220 | LabTest Zote"},{"key":"2026081219362938700_oyag291-B97","author":"MPR - Home"},{"key":"2026081219362938700_oyag291-B98","author":"Lynparza 150mg x56 Tablets","year":"2026"},{"key":"2026081219362938700_oyag291-B99","author":"Olaparib 150 mg Tablet 60\u2019s Substitute\u2014Alternatives, Uses and Benefits\u2014Apollo Pharmacy","year":"2026"},{"key":"2026081219362938700_oyag291-B100","author":"Buy Olaparib 150mg Tablet Online: View Uses, Side Effects, Price, Substitutes","year":"2026"},{"key":"2026081219362938700_oyag291-B101","doi-asserted-by":"publisher","first-page":"1479966","DOI":"10.3389\/fpubh.2025.1479966","article-title":"Cost-effectiveness analysis of population-based BRCA1\/2 testing, family-history-based BRCA1\/2 testing, and symptom-based screening for breast and ovarian cancer in China","volume":"13","author":"Zhao","year":"2025","journal-title":"Front Public Health"},{"key":"2026081219362938700_oyag291-B102","author":"BRCA 1\/2"},{"key":"2026081219362938700_oyag291-B103","author":"Panel Cancer DE Mama BRCA1-BRCA2"},{"key":"2026081219362938700_oyag291-B104","author":"Genetic Screening in Mexico | Cost \u25b7 TOP 10+ Clinics 2026"},{"key":"2026081219362938700_oyag291-B105","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1590\/S1415-475738320140204","article-title":"Costs of genetic testing: supporting Brazilian public policies for the incorporating of molecular diagnostic technologies","volume":"38","author":"Schlatter","year":"2015","journal-title":"Genet Mol Biol"},{"key":"2026081219362938700_oyag291-B106","author":"Compra Lynparza 150mg 56 Tab\u2014Astrazeneca\u2014Hidrocortisona\/ Cloramfenicol\/ Benzoca\u00edna - Precio Bajo. Vida Farmacias - Farmacia Online de Especialidad. Accessed","year":"2026"},{"key":"2026081219362938700_oyag291-B107","author":"Zejula 100 mg con 90 capsulas - Niraparib"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag291\/70111165\/oyag291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag291\/70111165\/oyag291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag291\/70111165\/oyag291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:36:35Z","timestamp":1786577795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag291\/8742107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag291","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,25]]},"article-number":"oyag291"}}